Adi Diab Selected Research

cyclopropapyrroloindole

1/2022	Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
1/2022	Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma.
1/2021	Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis.
1/2019	Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience.
10/2018	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.
10/2018	Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Adi Diab Research Topics

Disease

64	Neoplasms (Cancer) 10/2023 - 05/2006
54	Melanoma (Melanoma, Malignant) 10/2023 - 05/2006
7	Colitis 10/2023 - 10/2018
5	Brain Neoplasms (Brain Tumor) 04/2022 - 01/2017
5	Disease Progression 12/2019 - 03/2016
4	Autoimmune Diseases (Autoimmune Disease) 05/2023 - 01/2016
4	Arthritis (Polyarthritis) 01/2023 - 12/2017
4	Breast Neoplasms (Breast Cancer) 04/2022 - 10/2016
4	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 11/2019
3	Acute Kidney Injury (Acute Renal Failure) 10/2023 - 01/2021
3	Infections 01/2023 - 09/2006
3	Enterocolitis 01/2022 - 10/2018
3	Neoplasm Metastasis (Metastasis) 10/2020 - 12/2019
3	Dermatitis 09/2019 - 02/2017
3	Diarrhea 12/2018 - 10/2018
3	Experimental Melanoma 11/2017 - 05/2006
2	Myositis (Idiopathic Inflammatory Myopathies) 10/2023 - 01/2023
2	Nephritis 03/2023 - 01/2023
2	Myasthenia Gravis 01/2023 - 11/2019
2	Necrosis 01/2023 - 12/2017
2	Inflammation (Inflammations) 01/2023 - 01/2019
2	Pneumonia (Pneumonitis) 01/2023 - 01/2020
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2022 - 01/2020
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 01/2020
2	Interstitial Nephritis (Tubulointerstitial Nephritis) 01/2021 - 01/2019
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021 - 01/2020
2	Hypothyroidism 01/2021 - 10/2018
2	Headache (Headaches) 01/2021 - 01/2018
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 09/2006
2	Fatigue 01/2021 - 11/2019
2	Leukemia 01/2020 - 01/2013
2	Bullous Pemphigoid (Pemphigoid) 10/2018 - 02/2017
2	Exanthema (Rash) 12/2017 - 12/2016
2	Grover's disease 01/2017 - 01/2016
1	Urogenital Neoplasms 10/2023
1	Myocarditis (Carditis) 01/2023
1	Hepatitis 01/2023
1	Central Nervous System Vasculitis 01/2023
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2023
1	Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis) 01/2023
1	Cholangitis 01/2023
1	Squamous Cell Carcinoma of Head and Neck 10/2022
1	Carcinoma (Carcinomatosis) 10/2022
1	Urologic Neoplasms (Urological Cancer) 10/2022
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2022

Drug/Important Bio-Agent (IBA)

40	Immune Checkpoint InhibitorsIBA 10/2023 - 01/2016
17	NivolumabIBA 10/2023 - 10/2018
13	IpilimumabIBA 01/2022 - 01/2016
12	Biomarkers (Surrogate Marker)IBA 12/2022 - 01/2016
10	bempegaldesleukinIBA 10/2023 - 01/2019
7	pembrolizumabIBA 01/2022 - 01/2016
6	cyclopropapyrroloindoleIBA 01/2022 - 10/2018
6	Interleukin-2 (IL2)IBA 10/2021 - 01/2018
5	Infliximab (Remicade)FDA Link 10/2023 - 10/2018
5	CTLA-4 AntigenIBA 10/2022 - 03/2016
5	Proteins (Proteins, Gene)FDA Link 04/2022 - 05/2006
5	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2019 - 12/2017
4	AntibodiesIBA 01/2023 - 03/2016
4	LigandsIBA 03/2022 - 03/2016
4	CytokinesIBA 01/2021 - 12/2016
4	SteroidsIBA 01/2019 - 10/2018
4	DNA (Deoxyribonucleic Acid)IBA 10/2016 - 05/2006
3	Interleukin-6 (Interleukin 6)IBA 01/2023 - 01/2016
3	Programmed Cell Death 1 ReceptorIBA 03/2022 - 10/2020
3	dabrafenibIBA 09/2019 - 08/2016
3	Neoplasm Antigens (Tumor Antigens)IBA 12/2016 - 01/2013
2	relatlimabIBA 03/2023 - 11/2022
2	tilsotolimodIBA 12/2022 - 01/2021
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2022
2	InterferonsIBA 01/2021 - 10/2020
2	AntigensIBA 01/2021 - 09/2006
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 01/2018
2	trametinibIBA 01/2018 - 08/2016
2	tocilizumab (atlizumab)FDA Link 12/2017 - 01/2016
2	DNA VaccinesIBA 01/2013 - 09/2006
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2023
1	Dextrans (Dextran)FDA Link 01/2023
1	Tumor Necrosis Factor InhibitorsIBA 01/2023
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2023
1	Methotrexate (Mexate)FDA LinkGeneric 01/2023
1	Interleukin-6 InhibitorsIBA 01/2023
1	Antirheumatic Agents (DMARD)IBA 01/2023
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2023
1	utomilumabIBA 10/2022
1	ProdrugsIBA 10/2022
1	Cisplatin (Platino)FDA LinkGeneric 10/2022

Therapy/Procedure

58	Therapeutics 10/2023 - 01/2013
24	Immunotherapy 03/2023 - 09/2014
5	Radiotherapy 04/2022 - 10/2018
2	Transplantation 01/2023 - 01/2021
2	Drug Therapy (Chemotherapy) 10/2022 - 10/2016
2	Liver Transplantation 03/2022 - 01/2019
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022 - 01/2018
2	Hematopoietic Stem Cell Transplantation 01/2021 - 09/2006
2	Organ Transplantation 06/2019 - 01/2019
2	Precision Medicine 01/2017 - 01/2016
2	Cryosurgery 12/2016 - 10/2016
2	Ligation 05/2010 - 05/2006
1	Immunomodulation 12/2022
1	Aftercare (After-Treatment) 12/2022